PFM
DYN icon

Privium Fund Management’s Dyne Therapeutics DYN Stock Holding History

Privium Fund Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-27,566
Closed -$239K – 61
2025
Q2 		$239K Hold
27,566
– – 0.05% 52
2025
Q1 		$288K Buy
27,566
+7,200
+35% +$103K 0.08% 51
2024
Q4 		$480K Buy
20,366
+5,350
+36% +$158K 0.11% 45
2024
Q3 		$539K Buy
15,016
+1,000
+7% +$39.8K 0.13% 47
2024
Q2 		$486K Buy
+14,016
New +$407K 0.12% 56

Other funds holding DYN

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Privium Fund Management's DYN Position: Q3 2025 in Review

Privium Fund Management sold out of Dyne Therapeutics (DYN) in Q3 2025, closing a stake of 27,566 shares — an estimated $239K sold.

Privium Fund Management first reported a position in DYN in Q2 2024 and held it in 5 quarters. The position peaked at $539K in Q3 2024. 207 funds tracked by Wall St. Rank hold DYN as of Q3 2025.

  • Privium Fund Management reported no remaining Dyne Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Privium Fund Management sold 27,566 Dyne Therapeutics shares in Q3 2025, an estimated $239K.
  • Privium Fund Management first reported a position in Dyne Therapeutics in Q2 2024 and held it in 5 quarters.
  • Privium Fund Management's Dyne Therapeutics position peaked at $539K in Q3 2024.
  • 207 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q3 2025.

Based on Privium Fund Management's 13F filing for Q3 2025, filed 4 Nov 2025.